The Digital Transformation In Radiology

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

On this episode of I Don’t Care, Host Kevin Stevenson talked with Dr. Moira Scheike, Founder of Cubismi and a board-certified radiologist specializing in cancer imaging. She invented 5D medical imaging technology. Cubismi is an interactive digital diagnostics pioneer who personalizes actionable visualizations and precision insights to transform and empower each professional interaction and patient journey. The duo talked about the cause and effect of the decline in the radiology job market, and how it can be reversed, and 5D imaging technology.

When it comes to imaging, the practice of radiology relies on outdated technology. When it comes to the digital transformation in radiology, 90 percent of the data is imaging. The industry also hasn’t benefitted from a digital transformation, which has left it open to high error rates and failures in disease detection. Schieke believes the field is poised for innovation and investment, both of which she argues is vital for rejuvenating the sector.

“We can think about it from two angles: what can we do about in the here and now, and immediately to address what are our major pains for the radiologist and healthcare systems dealing with huge problems around diagnostics,” Scheike said. “…in the long term, the big long term view, is we all know we have this vision for the future, a precision medicine future.”

The technological future Scheike refers to involves cloud computing and artificial intelligence. The challenges lie in stepping through and dealing with the current problems and then getting into the future. Another major problem is that the radiology job market is declining, with little investment being directed into the field over the past decade.

Listen to Previous Episodes of I Don’t Care!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More